Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read more on SRPT stock here.

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

In the full year 2024, Sarepta recorded a net income of $235.2 million. Sarepta ended Q1 2025 with $647.5 million in cash, cash equivalents, and investments. Conclusion ...

Sarepta Therapeutics is down 83.1% since the beginning of the year, and at $20.91 per share, it is trading 87.2% below its 52-week high of $163.85 from June 2024.

Pharma Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients By Angus Liu Jun 16, 2025 10:58am ...

Sarepta Therapeutics said the Duchenne muscular dystrophy patient recently had a cytomegalovirus infection, which can damage the liver and may have contributed to the fatality.

Investor Contact: Ian Estepan 617-274-4052 iestepan@sarepta.com Media Contacts: Tracy Sorrentino 617-301-8566 tsorrentino@sarepta.com Kara Hoeger 617-710-3898 KHoeger@sarepta.com ...

Sarepta Therapeutics (NasdaqGS:SRPT) saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year ...

Sarepta halted Elevidys shipments for non-ambulatory patients and paused dosing in the ENVISION trial. Market-moving news hits Benzinga Pro first—get a 30-minute edge and save 60% this 4th of July.

We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against other worst ...

Sarepta said Sunday that the latest patient death occurred in an ongoing trial of the gene therapy. The patient had died after experiencing acute liver failure, similar to what killed the patient ...